Vaccines in the 21st Century

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Vaccines and Public Health".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2537

Special Issue Editor


E-Mail Website
Guest Editor
Center for Fundamental and Applied Microbiomics, Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA
Interests: microbiology; bioinformatics; soil microbiome; cell stress; microbial symbiosis; cyanobacteria
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The 21st century has experienced several outbreaks, impacting human health like never before. The long list includes COVID-19, Ebola virus disease, severe acute respiratory syndrome (SARS), H1N1 influenza, monkeypox, zika virus, and nipa virus.

The scientific community, on the contrary, has been working relentlessly on finding solutions and has developed successful vaccines. This Special Issue aims to attract high-quality, cutting-edge research on all facets of vaccine research including, but not limited to, vaccine development, delivery strategies, molecular and immunological mechanisms of vaccines, vaccine safety, and effectiveness against newer evolving diseases during the last two decades.

We are seeking original articles, review articles, systematic reviews, communications, perspectives, case and brief reports, and all other article types as accepted by the journal. All manuscripts will undergo a rigorous peer-review process.

We look forward to receiving your quality contributions to this Special Issue.

Dr. Soumyadev Sarkar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine
  • vaccination
  • vaccine development
  • vaccine design
  • vaccine safety

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

13 pages, 2016 KiB  
Commentary
Summary of the Current Status of DNA Vaccination for Alzheimer Disease
by Caterina Vicidomini, Nicola Borbone, Valentina Roviello, Giovanni N. Roviello and Giorgia Oliviero
Vaccines 2023, 11(11), 1706; https://doi.org/10.3390/vaccines11111706 - 10 Nov 2023
Cited by 2 | Viewed by 1991
Abstract
Alzheimer disease (AD) is one of the most common and disabling neuropathies in the ever-growing aged population around the world, that especially affects Western countries. We are in urgent need of finding an effective therapy but also a valid prophylactic means of preventing [...] Read more.
Alzheimer disease (AD) is one of the most common and disabling neuropathies in the ever-growing aged population around the world, that especially affects Western countries. We are in urgent need of finding an effective therapy but also a valid prophylactic means of preventing AD. There is a growing attention currently paid to DNA vaccination, a technology particularly used during the COVID-19 era, which can be used also to potentially prevent or modify the course of neurological diseases, including AD. This paper aims to discuss the main features and hurdles encountered in the immunization and therapy against AD using DNA vaccine technology. Ultimately, this work aims to effectively promote the efforts in research for the development of safe and effective DNA and RNA vaccines for AD. Full article
(This article belongs to the Special Issue Vaccines in the 21st Century)
Show Figures

Figure 1

Back to TopTop